The Zika virus (ZIKV) outbreak in the Americas has caused Background. international concern due to neurological sequelae linked to the infection, such as microcephaly and Guillain-Barré syndrome (GBS). The World Health Organization stated that there is "sufficient evidence to conclude that Zika virus is a cause of congenital abnormalities and is a trigger of GBS". This conclusion was based on a systematic review of the evidence published until 30.05.2016. Since then, the body of evidence has grown substantially, leading to this update of that systematic review with new evidence published from 30.05.2016 -18.01.2017, update 1.
By March 9, 2017, 31 countries had reported microcephaly or other congenital central nervous system (CNS) abnormalities potentially associated with ZIKV infection and 23 had reported an increase in the incidence of the immune-mediated condition Guillain-Barré syndrome (GBS) or laboratory confirmed ZIKV in persons with GBS (WHO situation report 10.03.2017).
The causal association between ZIKV and adverse neurological outcomes has now been examined in many systematic and nonsystematic reviews of research 1, 2 . Case reports of other conditions in people with ZIKV infection, including immune-mediated idiopathic thrombocytopaenia purpura (ITP), have also been published [3] [4] [5] [6] .
The World Health Organization (WHO) based its assessment, that there is "sufficient evidence to conclude that Zika virus is a cause of congenital abnormalities and is a trigger of GBS" (WHO Zika causality statement), on a review of systematically identified studies up to May 30, 2016 and nonsystematically identified studies up to July 29, 2016 7 . The review addressed specific questions about 10 dimensions of causal associations, based on the work of Bradford Hill 8 and organised as a causality framework (Supplementary Table 1 ) that covers: temporality (cause precedes effect); biological plausibility of proposed biological mechanisms; strength of association; exclusion of alternative explanations; cessation (reversal of an effect by experimental removal of, or observed decline in, the exposure); dose-response relationship; experimental evidence from animal studies; analogous cause-and-effect relationships found in other diseases; specificity of the effect; and the consistency of findings across different study types, populations and times. The review included 108 articles about congenital abnormalities or GBS but there was no, or insufficient evidence to answer questions in several dimensions of the causality framework 7 . The causality framework included questions about ITP, but the review authors judged the number of published articles to be too low to assess causality. Since the WHO statement and accompanying publication, about 200 scientific publications every month are added to the body of evidence about all aspects of research about ZIKV.
A living systematic review would help to overcome some of the challenges of keeping up to date with the high volume of ZIKV research publications. A living systematic review is a systematic review that is "continually updated, incorporating relevant new evidence as it becomes available" 9 , which can help in fields where evidence is emerging rapidly and where new review outcomes might change policy or practice decision 10 . Technical solutions are available to facilitate the reviewing process, such as automated searching and deduplication and computer-assisted screening of article titles and abstracts, increase the efficiency and speed of a review team and transform the review into a living document.
This article aims to fulfil two separate objectives. First, we update our systematic review 7 with new evidence published from May 30, 2016 to January 18, 2017 about all 10 dimensions of the causal associations between ZIKV and (a) congenital brain abnormalities, including microcephaly, in the foetuses and offspring of pregnant women and (b) GBS/ITP in any population. Second, we describe the transition of the review into a living systematic review.
Methods

Classic protocol
We performed the review according to the protocol registered in PROSPERO CRD42016036693 (PROSPERO protocol). The eligibility criteria, information sources and search strategy, study selection and data extraction are the same as reported in the protocol and in the previous publication 7 . In brief, the search covers PubMed, Embase and LILACS electronic databases; the Pan American Health Organization (PAHO), WHO, the Centers for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC) websites; and several preprint databases (BioRxiv, PeerJ and ArXiv). Search terms included 'Zika virus' and 'ZIKV' and corresponding MESH terms. Two reviewers screen and select articles for inclusion and extract data independently. We included publications that held information on at least one of the ten dimensions of the causality framework, regardless of the study design 7 . We gathered publications systematically from May 30, 2016 to January 18, 2017 for this update. We refer to the previous version of the review as the baseline review 7 and to this current update as update 1. Reporting of the results follows the Preferred Reporting Items of Systematic reviews and Meta-Analyses (PRISMA) statement (Supplementary File 1)
.
From systematic review to living systematic review To keep up with the quantity of published research, we developed a living systematic review workflow (Supplementary File 2). We have identified three modules that could be automated ( Figure 1) . As of December 2017, module 1, searching and deduplication, and part of module 3, the output of the report have been automated. Reviewers can be notified daily with a list of new unique search results so that screening can be performed rapidly. Following manual data extraction and synthesis, the output can be updated semi-automatically. We use the online database Research Electronic Data Capture (REDCap) 12 to maintain the references, perform screening and extract data into piloted extraction forms. We plan to update the review twice per year with formal peer reviewed updates (Figure 2) , and continually through a web platform.
We synthesised the findings as narrative summaries of the evidence according to causality dimension and outcome, as previously described 7 , and compare them with the the baseline review. We use the term 'confirmation' to summarise findings of new studies included in update 1 if they report the same findings and Update 1 (U1) this version classic, manual systematic review. During 2017 automation of the workflow was conducted resulting in a projected Update 2 (U2) and 3 (U3) with more rapid throughput. LSR, living systematic review.
as those in the baseline review. We use the term 'expansion' of evidence if studies included in update 1 provide new findings.
Results
Between May 30, 2016 and January 18, 2017, we identified 2413 publications. After deduplication, we retained 1699 unique records. Based on screening of title and abstract, we discarded 1025 publications, retaining 674 items; after screening of the full text, 101 publications were included. Figure 3 shows the PRISMA flow diagram for this review
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. Seventy-seven publications held information on one or more dimensions of the causality framework on adverse congenital outcomes and 25 on GBS or idiopathic thrombocytopaenia purpura. Table 1 compares the included publications, study types and the causality dimension(s) they address in the baseline review 7 and update 1 of the review.
Adverse congenital outcomes
A detailed overview of the new evidence is provided in Table 2 and Supplementary Strength of association. We included five publications that confirm a strong association between ZIKV infection and adverse congenital outcomes 21, 22, 31, 40, 41 . The strength of association at an individual level was high but imprecise, owing to small sample sizes. Estimates from cohort studies 31,40 appeared to be lower than those from case-control studies 21, 22, 41 . The definition of the outcomes and the outcomes assessed, varied between studies. The risk of any adverse congenital outcomes was higher and more variable than the risk of microcephaly. The risk ratio for microcephaly between ZIKV unexposed and exposed was . In a prospective case-control study in Brazil, women with laboratoryconfirmed ZIKV had 55.5 (95% CI: 8.6-infinity) times the odds of having a baby with microcephaly compared with women without evidence of ZIKV infection 21 . A retrospective casecontrol study in Hawaii found an odds ratio of 11.0 (95% CI: 0.8-147.9) 41 . In the latter, however, exposure was assessed retrospectively using serology. . Maternal or foetal malnutrition, hypoxic-ischaemic lesions and Table 1 . Summary of included publications by study type and on which causality dimension they provide evidence. One publication can address multiple causality dimensions. Comparison between the current (U1) and the baseline review (BR, 7) stratified by outcome. GBS/ITP, adverse autoimmune outcomes (Guillain Barré syndrome/idiopathic thrombocytopaenia purpura). NA, not applicable; evidence about analogous conditions was not searched systematically; the dimension of consistency used information in items included for all other causality dimensions. Cessation. We did not find any new publications for this causality dimension. Evidence is still lacking on the effect of intentional removal due to lack of vaccination or elimination of mosquitoes on a large scale.
Exclusion of alternatives.
Condition and version
Dose-response.
There is still no direct evidence about the association between Zika viral load and probability of adverse congenital outcome in observational studies, or of an association between symptomatic status and outcome. . The body of evidence coming from animal studies has grown; both in mice and macaques, congenital anomalies such as intra-uterine growth restriction and signs of microcephaly were observed after ZIKV infection 78,84,85 .
Analogy. As for the baseline review, evidence for this dimension was not reviewed systematically because our search strategy did not include terms for other infections or conditions. Studies included in this version of the review confirm the analogy between congenital ZIKV and TORCH infections 87 . Vertical transmission of West Nile virus and dengue virus were summarised in the baseline review. In update 1, we included a case series Specificity. We included one study 89 , suggesting an expansion of evidence of a distinct congenital Zika syndrome (CZS) 89 . In a review of 34 published reports, the authors suggest five congenital abnormalities that, in conjunction, comprise a pattern that is unique to ZIKV: severe microcephaly with overlapping cranial structures, subcortical location of brain calcifications, macular scarring and retinal mottling, congenital contractures and early pyramidal and extrapyramidal symptoms 
Conclusion.
The evidence added in update 1 of the review confirms the conclusion of a causal association between ZIKV and adverse congenital outcomes. New findings expand the evidence base in the dimensions of biological plausibility, strength of association, animal experiments and specificity. In vitro and in vivo studies elucidate pathways on how these outcomes likely occur. Conclusive evidence on the strength of association is lacking. Studies provide crude overall measures of association, not taking into account potential co-factors.
GBS/ITP
In the search period for update 1 of the review, an additional 154 cases of ZIKV-related GBS 95 and 11 ZIKV-related cases of ITP 3-6 were described in 18 studies. Table 3 summarises the evidence for specific questions in each of 10 causality dimensions (detailed overview in Supplementary Table 3 ).
Temporality. We found an additional 17 publications that confirmed that ZIKV infection preceded the GBS or ITP at an individual level 3,5,6,95-108 or at a population level 103,109-111 . ZIKV infections seems to be followed by GBS on average between 5 and 10 days. In one case series from Colombia 103 , the authors distinguished between rapid onset of GBS symptoms after ZIKV symptoms (para-infectious) and post-infectious onset, with an asymptomatic period after ZIKV symptoms before the start of GBS symptoms. Biological plausibility. We did not find any publications about the biological plausibility of ZIKV as a cause of GBS or ITP.
Strength of association.
We did not find any comparative observational studies during the search period for update 1. Several surveillance studies confirmed an increase in notified GBS cases during ZIKV outbreaks at the population level
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. Rate ratios were significantly higher for Brazil, Colombia, the Dominican Republic, El Salvador, Honduras, Suriname and Venezuela when comparing pre-ZIKV GBS incidence and the incidence during the outbreak 111 ; this ratio ranged from 2.0 (95% CI: 1.6-2.6) to 9.8 (95% CI: 7.6-12.5).
Exclusion of alternatives.
We included 11 publications 4-6,95,98,99,101,103,104,111,112 that expanded the list of alternative causes for autoimmune disease that were excluded, such as infections, vaccines, other system illnesses and medication, drugs or other chemicals. Many GBS cases in these publications had serological evidence of previous exposure to DENV, as seen in the baseline review. It remains unclear how large the potential role of co-factors such as antibody dependent enhancement are.
Cessation. We did not identify any publications with evidence about the effect of intentional removal/elimination/prevention of ZIKV on either GBS or ITP. An additional publication confirmed evidence that the natural removal of ZIKV resulted in a decrease in GBS cases in Brazil, Colombia, Dominican Republic, El Salvador, Honduras, Suriname and Venezuela 104,111 .
Dose-response. We did not identify any publications about this dimension for either GBS or ITP.
Animal experiments. No additional evidence from animal experiments was identified that support the association between ZIKV infection and GBS/ITP development.
Analogy.
As for the baseline review, evidence for this dimension was not reviewed systematically because our search strategy did not include terms for other infections or conditions. We did not identify any new publications addressing this dimension for either GBS or ITP.
Specificity.
We did not identify any new publications addressing this dimension for either GBS or ITP.
Consistency. Studies included in update 1 confirmed the consistency of the evidence for 3 of 4 questions about the association between ZIKV and GBS. By geographical region, ZIKV transmission has been associated with the occurrence of GBS in 2 of 4 regions; increased GBS incidence has been reported in the WHO regions of the Americas and the Western Pacific region, but not in the African or Southeast Asian region, despite recent ZIKV circulation 113 . By study design, the association between ZIKV infection and GBS has been found at individual and population level and with different study designs. By population, ZIKV infection has been linked to GBS in ZIKV endemic regions 4-6,95,96,98-101,103-105,109,111,114 and travellers from non-affected countries who were exposed in these endemic regions 3,97,102,106,112 . There was insufficient evidence to examine the consistency of evidence about ZIKV and ITP.
Conclusion.
The body of evidence has grown during the search period for update 1 but only for dimensions that were already populated in the original publication for GBS. There is still a limited understanding of the biological pathways that potentially cause the occurrence of autoimmune disease following ZIKV infection. Additionally, prospective comparative epidemiological studies are still lacking. It remains unclear how co-factors such as age and previous exposure to flaviviruses influences the risk of developing GBS. The evidence supports a temporal association between ZIKV and ITP but there is an absence of evidence for other dimensions of causality.
Search results from January 19, 2017 to January 05, 2018 Automated search and deduplication processes identified 2410 publications about any aspect of ZIKV infection. The next update of this review will address causality dimensions in the realm of epidemiological studies; strength of association, dose-response relationship, specificity and consistency.
Discussion
Statement of principal findings. This systematic review confirms evidence of a causal association between ZIKV and adverse congenital outcomes and between ZIKV and GBS, although evidence about biological plausibility is still lacking. We assessed evidence about an association between ZIKV and ITP but found that this only addressed the dimension of temporality. The review is transitioning from classic systematic review methods to those of a living systematic review.
Strengths and limitations of the study. The strengths of this study are the systematic approach to the identification, selection and extraction of data following a causality framework that provides a structure for the consideration of heterogeneous sources of evidence and a large set of review questions. Automation of the review output allows rapid updating of tables of results. We have also developed methods to automate search and deduplication of search results to make the transition to a living systematic review that will allow continual updating of results. The main limitation of the classic systematic review of such a complex topic is the high workload and time required to maintain it. Another limitation, resulting from the large number of review questions, is the time taken to resolve interreviewer differences in interpretation of eligibility criteria. This could have resulted in subjectivity over decisions about inclusion in the review. Although a second reviewer checked all extractions, changes in the review team could introduce inconsistency. As in the baseline review, we used case definitions as authors described them in individual publications. This potential source of information bias is likely to decrease over time as standardised case definitions and protocols are adopted 115 . As in the previous version, we did not systematically apply quality assessment tools to individual studies. Because much of the technical infrastructure was built as the evidence emerged, output was delayed. As much of the LSR methodology was novel, it took time to find a balance between speed and efficiency.
Strengths and weaknesses in relation to other publications.
Our systematic review differs from most standard reviews because of the number of questions within the dimensions of the causality framework and the number of outcomes. Other recent examples of living systematic reviews only distinguish between two study types (RCT and non-RCT) 116 and are guided by only a small set of review questions 117, 118 . Our review conclusion, confirming evidence for a causal association between ZIKV and GBS differs from that of a review 119 of the findings of four case reports 104,120-122 and one case-control study 123 . The authors found insufficient evidence to confirm the presence of an acute motor axonal neuropathy variant of GBS. They did not, however, suggest an alternative explanation for the increase in incidence of GBS in the countries that experienced ZIKV outbreaks. The two versions of our review included 64 publications about ZIKV and GBS across ten dimensions of causality.
Meaning of the study: possible mechanisms and implications for basic researchers, clinicians or policymakers. The conclusions on the causal relation between ZIKV and adverse congenital outcomes and ZIKV and GBS did not change with this update. We found insufficient evidence about the association between ZIKV and ITP to state with certainty that there is a causal association. The total volume of evidence about the association between ZIKV and GBS is less than for the association with adverse congenital outcomes. There is, in particular a lack of published research to elucidate biological mechanisms for direct neuronal or autoimmune damage in GBS 124 .
The descriptive data about the numbers and types of different studies over time illustrates how evidence about a new, or reemerging, infection emerges over time. The evidence from many regions that were affected by the ZIKV outbreak remains limited to anecdotal evidence of adverse outcomes, in the form of case reports or case series. The slowing of ZIKV transmission in 2017 means that fewer people are being affected by ZIKV and its complications and fewer people are being enrolled into prospective studies. Further progress in epidemiological research will rely more heavily on research consortia who are contributing to joint analyses of data from existing studies.
Unanswered questions and future research. As the volume and complexity of the evidence in different causality dimensions accumulates, the need for expert input and interpretation of the findings of this systematic review increases. The focus of research on ZIKV and causal associations with different types of adverse outcomes is also changing. For congenital abnormalities resulting from ZIKV vertical transmission, epidemiological research should examine CZS in comparative studies, quantify the strength of association with ZIKV, clarify associations with gestational age, symptomatology and viral load and further investigate potential co-factors such as previous dengue infection and flavivirus vaccination. WHO standardised study protocols provide suggestions for exclusion of alternative explanations and exploration of co-factors (Harmonization of ZIKV Research Protocols). For GBS, epidemiological studies are needed to quantify the association with ZIKV more precisely, but also to determine whether there are distinct phenotypes resulting from autoimmune mechanisms or direct neuronal involvement. For ITP, additional evidence across all causality dimensions is needed.
Planned updates of a living systematic review. Living systematic review methodology and techniques will continue to develop. Since a chain is only as strong as its weakest link, any processing step has the potential to slow down a living systematic review. Clearly defined protocols that define update frequencies and throughput speed of different actors in the publishing process are vital. The next update of the systematic reviews will use living systematic review methods to assess the evidence for 2017 and early 2018 (update 2, Figure 2) . The review will, for the first time, separate evidence from epidemiological study designs from in vitro and in vivo laboratory studies. We will narrow down the inclusion criteria based on study type. Epidemiological evidence will address the causality dimensions 'strength of association', 'dose-response', 'specificity' and 'consistency'. Several co-factors might play a role in the strength of association. Thus, we will continue to collect information on previous dengue virus infection, yellow fever vaccination status, socioeconomic status, gestational age and others factors
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that might play a role in the severity of the outcome. We will amend the protocol with a more focused search strategy and inclusion criteria (Supplementary File 3) . Systematic reviews of questions addressed by laboratory studies are less frequent than those addressing epidemiological research questions. There is still need to update understanding of the causality dimensions 'biological plausibility' and 'animal experiments', particularly to increase our understanding of biological pathways for ZIKV effects on the peripheral nervous system and the immune system. We encourage and welcome collaboration from scientists with expertise in these fields to update systematic reviews for these causality dimensions.
Conclusion. This systematic review confirms previous conclusions that ZIKV is a cause of congenital abnormalities, including microcephaly and is a trigger of GBS. Evidence suggests an association with idiopathic thrombocytopaenia purpura but is not conclusive. The transition to living systematic review techniques and methodology provides a proof of concept for the use of these methods to synthesise evidence about an emerging pathogen such as ZIKV, ultimately leading to integration in the whole public health information cycle 125 . With the infrastructure for living systematic review methods and open source access to the software and outputs, we aim to enhance outbreak preparedness and the study of emerging and re-emerging pathogens.
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all aspects of it's complex objective. Please find below my comments:
For the methods I would have liked to see more information. This review should be able to stand on it's own without the reader having to find the baseline review to find important methodological information:
I would have liked to see inclusion/exclusion criteria for the study (something that could easily be in a figure or table to save room). Please include your search strategy as a supplementary file (just Embase would be sufficient). It sounds like a very simple search the way you've described it in the methods. Also would have liked more information about who designed the search (e.g. information specialist, librarian, the researchers) and if it was peer reviewed using PRESS. Finally, in the "analogy" section of the results you indicate this wasn't reviewed in the baseline review as the search strategy didn't include terms for it. This indicates to me that you must have updated your search between the baseline review and the update, but you don't say this in your methods. There is no assessment for methodological quality, which you do address in your limitations. I think this is an important step when you're including different study designs (although can also be challenging for the same reason). Probably not appropriate to give the same weight to a case report as a cross-sectional study, or an animal experiment and an epidemiological study.
General: I find Table 1 a bit difficult to read, maybe because instinctively I'd expect the column for "U1, N" to be the total number of studies in the update, rather than just the new studies added with this update. This only becomes obvious when you look at rows like "case series" and you see the U1 has less studies than BR. If you keep this structure, it would be nice to add another column that has total N (as it was the total N that you're drawing conclusion from, the BR and U1 don't stand alone). I feel this review is premature in saying that it is transitioned to a living systematic review. The intention of the living systematic review is to provide the reader with up to date evidence so the lag between the search and publication is minimize. The authors even define a living systematic review as "a systematic review that is continually updated, incorporating relevant new evidence as it becomes available". The search for this study ended in January 2017, and technically is out of date even for a regular systematic review (which we try to publish within a year). The authors say that they plan to update the review twice per year with formal peer review updates, but if that was the case then another 2 reviews should have been done since this date. Additionally, they authors indicate that only module 1 and part of module 3 of their living systematic review automation were in place by December 2017, meaning this wasn't used for this update.
Figure 2 already looks to be out of date -in it they propose that U2 would be published by Feb 2018. If they were able to accomplish this then U2 might have been more appropriate to call a living systematic review (where search looks to be from Jan to Dec 2017, and publication is Feb 2018).
I think it would have been more appropriate to publish this as an update of the systematic review, publish a protocol for how they were going to transition to a living systematic review (where Figures 1 and 2 would be included), and then treat U2 as their 'baseline" living systematic review, at which point the "living" aspect of the review is turned on and updates are given every 6 months (as they proposed). Referee Expertise: Systematic reviews, living systematic reviews I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
Do
